Alemtuzumab in allogeneic hematopoetic stem cell transplantation

Expert Opinion on Biological Therapy

Volumn 11, Issue 8, 2011, Pages 1099-1111

  Poiré, Xavier ^a   Van Besien, Koen ^b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

alemtuzumab; allogeneic stem cell transplantation; graft versus host disease; T cell depletion

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ANTIHISTAMINIC AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUDARABINE; GANCICLOVIR; MELPHALAN; METHOTREXATE; PARACETAMOL; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; DONOR LYMPHOCYTE INFUSION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; INVASIVE ASPERGILLOSIS; LOW DRUG DOSE; LYMPHOCYTOPENIA; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; RIGOR; SALVAGE THERAPY; SINGLE DRUG DOSE; T CELL DEPLETION; T LYMPHOCYTE; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 79959889702     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.592824     Document Type: Review

References (109)

1. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010;11:2091-101
2. Perez-Simon JA, Kottaridis PD, Martino R, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. N Engl J Med 2010;363:2091-101
3. Wolff D, Gerbitz A, Ayuk F, et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 2010;16:1611-28
4. Waldmann H, Hale G. CAMPATH: from concept to clinic. Philos Trans R Soc Lond B Biol Sci 2005;360:1707-11 (Pubitemid 43997819)
5. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001;98:3192-204
6. Papadopoulos EB, Carabasi MH, Castro-Malaspina H, et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998;91:1083-90 (Pubitemid 28078314)
7. Hale G, Zhang MJ, Bunjes D, et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998;92:4581-90 (Pubitemid 29005860)
8. + selected grafts with recipients of unmanipulated grafts. Exp Hematol 1999;27:561-8 (Pubitemid 29125066)
9. Gribben JG, Hallek M. Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol 2009;144:818-31
10. Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002;20:205-13 (Pubitemid 34032613)
11. Risitano AM, Selleri C, Serio B, et al. Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol 2010;148:791-6
12. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-801
13. Tan HP, Donaldson J, Basu A, et al. Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. Am J Transplant 2009;9:355-66
14. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005;5:465-74 (Pubitemid 40313337)
15. + regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 2008;8:793-802 (Pubitemid 351347746)
16. + T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression. Am J Transplant 2008;8:338-47
17. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002;99:1071-8 (Pubitemid 34525573)
18. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000;96:2419-25
19. Gomez-Almaguer D, Ruiz-Arguelles GJ, et al. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2008;14:10-15 (Pubitemid 350286746)
20. Xia MQ, Hale G, Lifely MR, et al. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993;293:633-40 (Pubitemid 23244542)
21. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993;82:807-12 (Pubitemid 23221659)
22. Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998;22:185-91 (Pubitemid 28185349)
23. Rodig SJ, Abramson JS, Pinkus GS, et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006;12:7174-9 (Pubitemid 44974519)
24. Albitar M, Do KA, Johnson MM, et al. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer 2004;101:999-1008 (Pubitemid 39100434)
25. Matthews K, Lim Z, Afzali B, et al. Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab. Haematologica 2009;94:956-66
26. Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009;128:260-70
27. Penack O, Fischer L, Stroux A, et al. Serotherapy with thymoglobulin and alemtuzumab differentially influences frequency and function of natural killer cells after allogeneic stem cell transplantation. Bone Marrow Transplant 2008;41:377-83 (Pubitemid 351330733)
28. Ratzinger G, Reagan JL, Heller G, et al. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood 2003;101:1422-9 (Pubitemid 36182516)
29. Ferrajoli A, O'Brien SM, Cortes JE, et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 2003;98:773-8 (Pubitemid 36959274)
30. Golay J, Manganini M, Rambaldi A, Introna M. Effect of alemtuzumab on neoplastic B cells. Haematologica 2004;89:1476-83
31. Nuckel H, Frey UH, Roth A, et al. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Eur J Pharmacol 2005;514:217-24 (Pubitemid 40723643)
32. Stanglmaier M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol 2004;83:634-45 (Pubitemid 39317488)
33. Zhang Z, Zhang M, Goldman CK, et al. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res 2003;63:6453-7 (Pubitemid 37255196)
34. Lin TS, Flinn IW, Modali R, et al. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood 2005;105:289-91 (Pubitemid 40053095)
35. Rebello P, Cwynarski K, Varughese M, et al. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 2001;3:261-7 (Pubitemid 34784622)
36. Morris EC, Rebello P, Thomson KJ, et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 2003;102:404-6 (Pubitemid 36759683)
37. Tholouli E, Liakopoulou E, Greenfield HM, et al. Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia. Br J Haematol 2008;142:318-20 (Pubitemid 351987323)
38. Brett S, Baxter G, Cooper H, et al. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H. Immunology 1996;88:13-19
39. Bertz H, Spyridonidis A, Wasch R, et al. A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation. Biol Blood Marrow Transplant 2009;15:1563-70
40. Spyridonidis A, Liga M, Triantafyllou E, et al. Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia. Bone Marrow Transplant: published online 20 December 2010; doi: 10.1038/bmt.2010.308
41. Chakraverty R, Orti G, Roughton M, et al. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood 2010;116:3080-8
42. Bokhari S, Das-Gupta E, Russell N, Byrne J. Post-transplant lymphoproliferative disease following reduced intensity conditioning transplants incorporating alemtuzumab. Bone Marrow Transplant 2008;42:281-2
43. Hale G, Rebello P, Brettman LR, et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004;104:948-55 (Pubitemid 39043667)
44. Oshima K, Kanda Y, Nakahara F, et al. Pharmacokinetics of alemtuzumab after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab with or without CD52-positive malignancies. Am J Hematol 2006;81:875-9 (Pubitemid 44682191)
45. Mould DR, Baumann A, Kuhlmann J, et al. Population pharmacokinetics- pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 2007;64:278-91 (Pubitemid 47283867)
46. Delgado J, Thomson K, Russell N, et al. Results of alemtuzumab-based reducedintensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood 2006;107:1724-30 (Pubitemid 43242415)
47. Juliusson G, Theorin N, Karlsson K. et al. Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival. Bone Marrow Transplant 2006;37:503-10
48. Novitzky N, Thomas V, Hale G, Waldmann H. Ex vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukemia: graft-versus-host disease and graft-versus-leukemia effect. Transplantation 1999;67:620-6 (Pubitemid 29114228)
49. Jacobs P, Wood L. Immunohematopoietic stem cell transplantation: introduction and 35 years of development in South Africa-the historical and scientific perspective. Bone Marrow Transplant 2008;42(Suppl 1):S125-32
50. Barge RM, Starrenburg CW, Falkenburg JH, et al. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath in the bag as T-cell depletion: the Leiden experience. Bone Marrow Transplant 2006;37:1129-34 (Pubitemid 43871523)
51. von dem Borne PA, Beaumont F, Starrenburg CW, et al. Outcomes after myeloablative unrelated donor stem cell transplantation using both in vitro and in vivo T-cell depletion with alemtuzumab. Haematologica 2006;91:1559-62 (Pubitemid 44736125)
52. Novitzky N, Thomas V, du Toit C, McDonald A. Reduced-intensity conditioning for severe aplasia using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts leads to excellent engraftment and absence of GVHD. Bone Marrow Transplant 2009;43:779-85
53. Chakrabarti S, MacDonald D, Hale G, et al. T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. Br J Haematol 2003;121:109-18 (Pubitemid 36461276)
54. Mead AJ, Thomson KJ, Morris EC, et al. HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reducedintensity conditioning. Blood 2010;115:5147-53
55. Rizzieri DA, Koh LP, Long GD, et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007;25:690-7 (Pubitemid 350002925)
56. Rizzieri DA, Dev P, Long GD, et al. Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/ 6 HLA matched donors. Bone Marrow Transplant 2009;43:327-33
57. Ho AY, Pagliuca A, Kenyon M, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004;104:1616-23 (Pubitemid 39202266)
58. Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005;23:9387-93
59. van Besien K, Artz A, Smith S, et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005;23:5728-38
60. van Besien K, Kunavakkam R, Rondon G, et al. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant 2009;15:610-17
61. Lim ZY, Ho AY, Ingram W, et al. Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br J Haematol 2006;135:201-9 (Pubitemid 44401617)
62. Lim ZY, Pearce L, Ho AY, et al. Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. Br J Haematol 2007;138:517-26 (Pubitemid 47063029)
63. Malladi RK, Peniket AJ, Littlewood TJ, et al. Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML. Bone Marrow Transplant 2009;43:709-15
64. Craddock C, Nagra S, Peniket A, et al. Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 2010;95:989-95
65. Patel B, Kirkland KE, Szydlo R, et al. Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. Haematologica 2009;94:1399-406
66. Freytes CO, Loberiza FR, Rizzo JD, et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 2004;104:3797-803 (Pubitemid 39564460)
67. Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reducedintensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004;104:3865-71 (Pubitemid 39620131)
68. Thomson KJ, Morris EC, Bloor A, et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009;27:426-32
69. Cook G, Smith GM, Kirkland K, et al. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British society for blood and marrow transplantation. Biol Blood Marrow Transplant 2010;16:1419-27
70. Thomson KJ, Morris EC, Milligan D, et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 2010;28:3695-700
71. Morris E, Mackinnon S. Outcome following alemtuzumab (CAMPATH- 1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL). Transfus Apher Sci 2005;32:73-83 (Pubitemid 40292818)
72. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002;100:4310-16 (Pubitemid 35429668)
73. Peggs KS, Sureda A, Qian W, et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 2007;139:70-80 (Pubitemid 47389932)
74. Thomson KJ, Peggs KS, Smith P, et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 2008;41:765-70 (Pubitemid 351696339)
75. Peggs KS, Kayani I, Edwards N, et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol 2011;29:971-8
76. Hari P, Carreras J, Zhang MJ, et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008;14:236-45
77. Kenkre VP, Horowitz S, Artz AS, et al. T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed lymphoma. Predictors for survival after transplant relapse. Leuk Lymphoma 2011;52:214-22
78. Faulkner RD, Craddock C, Byrne JL, et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004;103:428-34 (Pubitemid 38140069)
79. Ingram W, Devereux S, Das-Gupta EP, et al. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. Br J Haematol 2008;141:235-43 (Pubitemid 351406220)
80. Dreger P, Dohner H, Ritgen M, et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010;116:2438-47
81. Crawley C, Szydlo R, Lalancette M, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005;106:2969-76 (Pubitemid 41565887)
82. Poire X, Artz A, Larson RA, et al. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma 2009;50:85-91
83. Crawley C, Lalancette M, Szydlo R, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005;105:4532-9 (Pubitemid 40720805)
84. Siegal D, Xu W, Sutherland R, et al. Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies. Bone Marrow Transplant 2008;42:51-6 (Pubitemid 352003424)
85. Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 2009;361:2309-17
86. Chewning JH, Castro-Malaspina H, Jakubowski A, et al. Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure. Biol Blood Marrow Transplant 2007;13:1313-23 (Pubitemid 47571031)
87. Bolanos-Meade J, Luznik L, Muth M, et al. Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplant 2009;43:477-80
88. Martinez C, Solano C, Ferra C, et al. Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a Phase II study. Biol Blood Marrow Transplant 2009;15:639-42
89. Schnitzler M, Hasskarl J, Egger M, et al. Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. Biol Blood Marrow Transplant 2009;15:910-18
90. Ruiz-Arguelles GJ, Gil-Beristain J, Magana M, Ruiz-Delgado GJ. Alemtuzumab-induced resolution of refractory cutaneous chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008;14:7-9 (Pubitemid 350286742)
91. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995;86:1261-8
92. Peggs KS, Thomson K, Hart DP, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004;103:1548-56 (Pubitemid 38168677)
93. Pollyea DA, Artz AS, Stock W, et al. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2007;40:1027-32 (Pubitemid 350142554)
94. van Besien K, Dew A, Lin S, et al. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma 2009;50:1809-17
95. Bonnefoy-Berard N, Vincent C, Revillard JP. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 1991;51:669-73
96. Kroger N, Shaw B, Iacobelli S, et al. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 2005;129:631-43 (Pubitemid 40825825)
97. Norlin AC, Remberger M. A comparison of Campath and Thymoglobulin as part of the conditioning before allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2010;86:57-66
98. Soiffer R, LeRademacher J, Ho V, et al. Impact of in vivo T-cell depletion on outcome of reduced intensity conditioning (RIC) hematopoetic cell transplantation (HCT) for hematological malignancies. Blood (ASH Annual Meeting Abstracts) 2010;116: abstract 2305
99. Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009;113:4992-5001
100. Lowdell MW, Craston R, Ray N, et al. The effect of T cell depletion with Campath-1M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia. Bone Marrow Transplant 1998;21:679-86 (Pubitemid 28159604)
101. Schmidt-Hieber M, Schwarck S, Stroux A, et al. Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion. Int J Hematol;91:877-85
102. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002;99:4357-63 (Pubitemid 34627201)
103. Lamba R, Carrum G, Myers GD, et al. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab. Bone Marrow Transplant 2005;36:797-802 (Pubitemid 41613303)
104. Lim ZY, Cook G, Johnson PR, et al. Results of a Phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation. Leuk Res 2009;33:244-9
105. Kline J, Pollyea DA, Stock W, et al. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant 2006;37:307-10
106. O'Donnell PH, Swanson K, Josephson MA, et al. BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. Biol Blood Marrow Transplant 2009;15:1038-48 e1
107. Carpenter B, Haque T, Dimopoulou M, et al. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation. Transplantation 2010;90:564-70
108. Chakrabarti S, Milligan DW, Pillay D, et al. Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood 2003;102:839-42 (Pubitemid 36917773)
109. Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002;100:1619-27 (Pubitemid 34925137)